SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
External view of Eli Lilly's world headquarters in Indianapolis
Manufacturing
Lilly to Invest $4.5B in New Indiana Manufacturing and R&D Center
Eli Lilly’s investment in the LEAP Research and Innovation District in Lebanon, Indiana, has now jumped to more than $13 billion.
October 2, 2024
 · 
2 min read
 · 
Tristan Manalac
Weeks Bridge of Harvard University
Job Trends
Improving Talent Recruitment, Retainment Key to Massachusetts Life Sciences: Report
Designed to create hundreds of jobs and add up to $1 billion to Massachusetts’ gross domestic product by the start of 2030, MassBio’s five-year strategic plan addresses challenges including skill gaps and talent shortages.
October 2, 2024
 · 
4 min read
 · 
Angela Gabriel
Podcast
BMS’ Schizophrenia Approval, Pfizer’s Sudden Sickle Cell Withdrawal and Roche’s Pharma Day
Bristol Myers Squibb wins approval for the first novel schizophrenia drug in decades; Pfizer pulls Oxbryta from the market; new IVF and abortion laws could derail women’s health research; Roche touts CDK inhibitor deal and obesity pipeline and BioSpace heads to Meeting on the Mesa.
October 2, 2024
 · 
1 min read
 · 
Heather McKenzie
Pictured: Amgen's office in Massachusetts/iStock,
Legal
Amgen Faces Class Action Lawsuit for Allegedly Hiding $10.7B Tax Bill From Investors
Amgen’s motion for dismissal was denied after a New York judge agreed the company did not sufficiently disclose to shareholders back taxes and penalties owed to the Internal Revenue Service.
October 2, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Sign at J&J Vision offices in Silicon Valley
Manufacturing
J&J to Invest $2B in North Carolina Manufacturing Facility, Create 420 Jobs
Johnson & Johnson is making the investment to help meet its 2030 target of launching 20 new medicines and expanding filings for approximately 50 other products.
October 2, 2024
 · 
2 min read
 · 
Tristan Manalac
Halftone collage banner, hands and diagram. Retro colors, paper cut elements, concept of business, saving, finance.
Deals
Royalty Financing Serves as Lifeline for Some Biopharma Companies in Uncertain Market
As traditional fundraising methods falter for smaller firms, the rise of royalty deals is reshaping how companies access capital, offering an alternative that bypasses equity dilution and debt.
October 2, 2024
 · 
5 min read
 · 
Ben Hargreaves
Hand holding pencil erasing an employee. Dismissal or bankrumptcy concept. Vector illustration.
Layoffs
Shattuck Labs to Lay Off 40% of Workforce
As it shifts focus to a death receptor 3 (DR3) antagonist antibody, Shattuck Labs is cutting a significant number of employees before the end of the year.
October 1, 2024
 · 
2 min read
 · 
Angela Gabriel
Brain shaped maze. Conceptual image of science and medicine. 3D illustration.
Schizophrenia
The Making of BMS’ Cobenfy: From Alzheimer’s to Schizophrenia
From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite the journey to market. Former Karuna and Lilly executives discuss the “accidental” and “serendipitous” discovery.
October 1, 2024
 · 
6 min read
 · 
Heather McKenzie
Pictured: Bristol Myers Squibb office in California
Legal
Federal Judge Dismisses $6.4B Lawsuit Against BMS Over Celgene Acquisition
District Judge Jesse Furman ruled that the plaintiff, UMB Bank, does not have standing to bring the case against Bristol Myers Squibb because it is not a properly appointed trustee for shareholders’ contingent value rights.
October 1, 2024
 · 
1 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS